-
1
-
-
75949103346
-
Development of a network to test strategies in cardiovascular cell delivery: The NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN)
-
Simari RD, Moyé LA, Skarlatos SI, Ellis SG, Zhao DX, Willerson JT, Henry TD, Pepine CJ,. Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res 2010; 1: 30-6.
-
(2010)
J Cardiovasc Transl Res
, vol.1
, pp. 30-36
-
-
Simari, R.D.1
Moyé, L.A.2
Skarlatos, S.I.3
Ellis, S.G.4
Zhao, D.X.5
Willerson, J.T.6
Henry, T.D.7
Pepine, C.J.8
-
2
-
-
68849129353
-
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
-
Cardiovascular Cell Therapy Research Network (CCTRN)
-
Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD,; Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and design for TIME: a phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J 2009; 158: 356-63.
-
(2009)
Am Heart J
, vol.158
, pp. 356-363
-
-
Traverse, J.H.1
Henry, T.D.2
Vaughan, D.E.3
Ellis, S.G.4
Pepine, C.J.5
Willerson, J.T.6
Zhao, D.X.7
Piller, L.B.8
Penn, M.S.9
Byrne, B.J.10
Perin, E.C.11
Gee, A.P.12
Hatzopoulos, A.K.13
McKenna, D.H.14
Forder, J.R.15
Taylor, D.A.16
Cogle, C.R.17
Olson, R.E.18
Jorgenson, B.C.19
Sayre, S.L.20
Vojvodic, R.W.21
Gordon, D.J.22
Skarlatos, S.I.23
Moyé, L.A.24
Simari, R.D.25
more..
-
3
-
-
77957348915
-
Late TIME: A phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction
-
Cardiovascular Cell Therapy Research Network
-
Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Simari RD, et al,.; Cardiovascular Cell Therapy Research Network. Late TIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J 2010; 37: 412-20.
-
(2010)
Tex Heart Inst J
, vol.37
, pp. 412-420
-
-
Traverse, J.H.1
Henry, T.D.2
Vaughan, D.E.3
Ellis, S.G.4
Pepine, C.J.5
Willerson, J.T.6
Zhao, D.X.7
Simpson, L.M.8
Penn, M.S.9
Byrne, B.J.10
Perin, E.C.11
Gee, A.P.12
Hatzopoulos, A.K.13
McKenna, D.H.14
Forder, J.R.15
Taylor, D.A.16
Cogle, C.R.17
Baraniuk, S.18
Olson, R.E.19
Jorgenson, B.C.20
Sayre, S.L.21
Vojvodic, R.W.22
Gordon, D.J.23
Skarlatos, S.I.24
Simari, R.D.25
more..
-
4
-
-
77955445600
-
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design
-
Cardiovascular Cell Therapy Research Network (CCTRN)
-
Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Simari RD, et al,.; Cardiovascular Cell Therapy Research Network (CCTRN). Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): rationale and design. Am Heart J 2010; 160: 215-23.
-
(2010)
Am Heart J
, vol.160
, pp. 215-223
-
-
Willerson, J.T.1
Perin, E.C.2
Ellis, S.G.3
Pepine, C.J.4
Henry, T.D.5
Zhao, D.X.6
Lai, D.7
Penn, M.S.8
Byrne, B.J.9
Silva, G.10
Gee, A.11
Traverse, J.H.12
Hatzopoulos, A.K.13
Forder, J.R.14
Martin, D.15
Kronenberg, M.16
Taylor, D.A.17
Cogle, C.R.18
Baraniuk, S.19
Westbrook, L.20
Sayre, S.L.21
Vojvodic, R.W.22
Gordon, D.J.23
Skarlatos, S.I.24
Simari, R.D.25
more..
-
5
-
-
77956040163
-
Multicenter cell processing for cardiovascular regenerative medicine applications: The Cardiovascular Cell Therapy Research Network (CCTRN) experience
-
Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koç JR, Ellis S, Taylor D, Cogle C, Moyé L, Simari R, Skarlatos S,. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy 2010; 12: 684-91.
-
(2010)
Cytotherapy
, vol.12
, pp. 684-691
-
-
Gee, A.P.1
Richman, S.2
Durett, A.3
McKenna, D.4
Traverse, J.5
Henry, T.6
Fisk, D.7
Pepine, C.8
Bloom, J.9
Willerson, J.10
Prater, K.11
Zhao, D.12
Koç, J.R.13
Ellis, S.14
Taylor, D.15
Cogle, C.16
Moyé, L.17
Simari, R.18
Skarlatos, S.19
-
6
-
-
47249153203
-
A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products
-
Gee AP, Sumstad D, Stanson J, Watson P, Proctor J, Kadidlo D, Koch E, Sprague J, Wood D, Styers D, McKenna D, Gallelli J, Griffin D, Read EJ, Parish B, Lindblad R,. A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products. Cytotherapy 2008; 10: 427-35.
-
(2008)
Cytotherapy
, vol.10
, pp. 427-435
-
-
Gee, A.P.1
Sumstad, D.2
Stanson, J.3
Watson, P.4
Proctor, J.5
Kadidlo, D.6
Koch, E.7
Sprague, J.8
Wood, D.9
Styers, D.10
McKenna, D.11
Gallelli, J.12
Griffin, D.13
Read, E.J.14
Parish, B.15
Lindblad, R.16
-
7
-
-
70849134277
-
Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers
-
Sutherland DR, Nayyar R, Acton E, Giftakis A, Dean S, Mosiman VL,. Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers. Cytotherapy 2009; 11: 595-605.
-
(2009)
Cytotherapy
, vol.11
, pp. 595-605
-
-
Sutherland, D.R.1
Nayyar, R.2
Acton, E.3
Giftakis, A.4
Dean, S.5
Mosiman, V.L.6
-
8
-
-
82555192610
-
Developing mechanistic insights into cardiovascular cell therapy-the Cardiovascular Cell Therapy Research Network (CCTRN) biorepository core laboratory rationale
-
Zierold C, Carlson MA, Obodo UC, Wise E, Piazza VA, Meeks MW, Vojvodic RW, Baraniuk S, Henry TD, Gee AP, Ellis SG, Moyé LA, Pepine CJ, Cogle CR, Taylor DA,. Developing mechanistic insights into cardiovascular cell therapy-the Cardiovascular Cell Therapy Research Network (CCTRN) biorepository core laboratory rationale. Am Heart J 2011; 162: 973-80.
-
(2011)
Am Heart J
, vol.162
, pp. 973-980
-
-
Zierold, C.1
Carlson, M.A.2
Obodo, U.C.3
Wise, E.4
Piazza, V.A.5
Meeks, M.W.6
Vojvodic, R.W.7
Baraniuk, S.8
Henry, T.D.9
Gee, A.P.10
Ellis, S.G.11
Moyé, L.A.12
Pepine, C.J.13
Cogle, C.R.14
Taylor, D.A.15
-
9
-
-
79960475582
-
Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: Results of the randomized controlled HEBE trial
-
HEBE Investigators
-
Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, van der Giessen WJ, Tio RA, Waltenberger J, ten Berg JM, Doevendans PA, Aengevaeren WR, Zwaginga JJ, Biemond BJ, van Rossum AC, Piek JJ, Zijlstra F,; HEBE Investigators. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 2011; 32: 1736-47.
-
(2011)
Eur Heart J
, vol.32
, pp. 1736-1747
-
-
Hirsch, A.1
Nijveldt, R.2
Van Der Vleuten, P.A.3
Tijssen, J.G.4
Van Der Giessen, W.J.5
Tio, R.A.6
Waltenberger, J.7
Ten Berg, J.M.8
Doevendans, P.A.9
Aengevaeren, W.R.10
Zwaginga, J.J.11
Biemond, B.J.12
Van Rossum, A.C.13
Piek, J.J.14
Zijlstra, F.15
|